Deal Statistics Quarterly, Q2 2002
In Vivo presents another installment of our quarterly review of dealmaking--in this case April through June 2002. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
You may also be interested in...
With so much interesting technology in the spine market today, valuations are sky high. Stryker's $135 million deal for Surgical Dynamics raises eyebrows for its low price. But if it isn't the boldest move in spine, Stryker's deal could very turn out to be a very good one, as the company gains an important foothold in the spinal cage market.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.